Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
Trinity Biotech(TRIB) GlobeNewswire News Room·2024-10-25 20:45
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech’s strategic expansion into the oncology diagnostics market. Prostate cancer is the most common non-skin canc ...